Rankings
▼
Calendar
KLRS Q1 2024 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena
KLRS
Kalaris Therapeutics Inc
$187M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$3M
Net Income
-$3M
EPS (Diluted)
$-0.68
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$31,000
Balance Sheet
Total Assets
$144M
Total Liabilities
$24M
Stockholders' Equity
$120M
Cash & Equivalents
$86M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$547,000
+100.0%
Operating Income
-$3M
-$43M
+94.1%
Net Income
-$3M
-$41M
+91.7%
← FY 2024
All Quarters
Q2 2024 →